These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 12146697)

  • 1. The importance of patient-specific radiation dose calculations for the administration of radionuclides in therapy.
    Siegel JA; Stabin MG; Brill AB
    Cell Mol Biol (Noisy-le-grand); 2002 Jul; 48(5):451-9. PubMed ID: 12146697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biokinetic and dosimetric modelling in the estimation of radiation risks from internal emitters.
    Harrison J
    J Radiol Prot; 2009 Jun; 29(2A):A81-A105. PubMed ID: 19454809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer standard for beta decay radionuclides in radiotherapy.
    Thieme K; Beinlich U; Fritz E
    Appl Radiat Isot; 2004; 60(2-4):519-22. PubMed ID: 14987695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
    Harrison JD; Muirhead CR
    Int J Radiat Biol; 2003 Jan; 79(1):1-13. PubMed ID: 12556326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation doses and risks from internal emitters.
    Harrison J; Day P
    J Radiol Prot; 2008 Jun; 28(2):137-59. PubMed ID: 18495991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncertainties in internal dose calculations for radiopharmaceuticals.
    Stabin MG
    J Nucl Med; 2008 May; 49(5):853-60. PubMed ID: 18413398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry.
    Traino AC; Ferrari M; Cremonesi M; Stabin MG
    Phys Med Biol; 2007 Sep; 52(17):5231-48. PubMed ID: 17762083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone-seeking radionuclides for therapy.
    Lewington VJ
    J Nucl Med; 2005 Jan; 46 Suppl 1():38S-47S. PubMed ID: 15653650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry of internal emitters.
    Sgouros G
    J Nucl Med; 2005 Jan; 46 Suppl 1():18S-27S. PubMed ID: 15653648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.
    Cremonesi M; Ferrari M; Di Dia A; Botta F; De Cicco C; Bodei L; Paganelli G
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):155-67. PubMed ID: 21386788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
    Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
    Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
    DeNardo GL; Siantar CL; DeNardo SJ
    Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
    Pauwels S; Barone R; Walrand S; Borson-Chazot F; Valkema R; Kvols LK; Krenning EP; Jamar F
    J Nucl Med; 2005 Jan; 46 Suppl 1():92S-8S. PubMed ID: 15653657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor control probability for tumor therapy with beta radionuclide interstitial injection.
    Chen Y; Geng J; Tian J; He Y; Chen S
    Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol.
    Zanzonico PB; Divgi C
    Semin Nucl Med; 2008 Mar; 38(2):S30-9. PubMed ID: 18243841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.